The biotech's partner says the vaccine didn't meet a study goal to show effectiveness. Stock drops almost 60%.
This biotech company's Soliris drug shows promise in treating several rare, life threatening diseases.
Analysts expect pomalidomide will win US approval in February, adding a potential blockbuster treatment to the biotech's drug lineup.
These stocks are supported by both solid fundamentals and strong technical positions.
Abbott also reports promising results ahead of a big medical meeting.
The approval of the rheumatoid arthritis treatment will help douse recent concerns about its pipeline.
Vivus shares dropped after it reported weaker-than-expected sales of its weight loss drug.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
All hail the bull market, which ended the week with a big rally. But it also is starting to look a little like 1987, which suffered an epic blow-out.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.